Skip to Main Content

WASHINGTON — Scott Gottlieb, President Trump’s nominee to lead the Food and Drug Administration, is taking a softer tone than the White House on the issue of a terminally ill patient’s “right to try” medicines still in the early stages of the agency’s approval process.

“If confirmed, I would commit to ensuring FDA has the right policies and processes in place to appropriately balance individual patients’ needs for access to investigational therapies,” Gottlieb wrote to Senator Patty Murray of Washington, the leading Democrat on the committee deciding Wednesday whether to advance his nomination, “while recognizing the importance of maintaining a rigorous clinical trial paradigm for testing investigational products and demonstrating safety and efficacy.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • No political or religious figure should have rhe rright to even suggest on the type of drug to be used in the terminally ill patient. Nor he or she shold have the authority to arbitrarely cut funds for research. This in itself demonstrates his or her total ignorance on the matter.

Comments are closed.